Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : IGT Pharma (V.IGT) Anti-Cancer Blockbuster!! -- Ignore unavailable to you. Want to Upgrade?

To: Stan Greene who wrote (41)	8/5/1998 1:06:00 PM
From: Ron Hardy	Read Replies (1) \| Respond to of 86

Hello Stan, Here is something to add to that NR. Fagan Report, Box 450, Grayland, WA 98547 (360) 371-3034 $99 a year. Reprint: August 4, 1998 At one time, the exclusive territory of this advisory was mining stocks. With gold malingering below $300, its editor, Mr. Brian Fagan, has expanded his territory to other "speculations". Two of his current speculations are Canadian biotechnology stocks. Mr. Fagan illustrates his recommendation with a chart comparing the seven stages of mineral exploration to seven stages of drug development - from early exploration (pre-clinical screening) to eventual production (eventual sale of new drug). He also suggests a further analogy: speculation in biotech companies like speculation in mining companies can be a form of Russian roulette. Mr. Fagan's two recommended biotechnology picks, both buys, are IGT Pharma Inc. (IGT-VSE, $1.05) and Inflazyme Pharmaceuticals (IZP-VSE, $0.86). One of IGT's key products is its anti-cancer drug, Anhydrovinblastine, or AVLB, for which it has had "impressive results in reducing cancer tumors" in preclinical trials. The company is now awaiting regulatory go-ahead to proceed with Phase 1 trials, preliminary testing in humans. Mr. Fagan says, "Studies have shown that companies with a product in Phase 1 clinical trials tend to support a market capitalization of about $25 million. Today IGT has a market capitalization of about $10 million; we're looking at a potential 150-per-cent gain for IGT over a nine-month period."